Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Internal Medicine
•
Myeloproliferative Neoplasms
•
Hematology
How do you manage and/or prevent ruxolitinib withdrawal syndrome?
Answer from: Medical Oncologist at Community Practice
Generally, tapering over a week or two is the best way to prevent it. If immediate discontinuation is needed, can consider using steroids.
Sign in or Register to read more
14673
Related Questions
In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?
How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?
For patients with essential thrombocythemia who develop venous thrombosis in the setting of elevated platelet counts, would you continue lifelong anticoagulation even after cytoreduction is achieved?
For patients with essential thrombocythemia already on prophylactic dose DOACs, do you defer starting aspirin?
Under which circumstances would you prefer ropeginterferon over hydroxyurea for patients with Polycythemia Vera?
How would one approach concomitant diffuse large B cell lymphoma and fibrotic phase myelofibrosis?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
Have you utilized a dose-reduced approach for elderly patients receiving frontline Pola-R-CHP similar to R-miniCHOP?
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?